FTC's Merger Concerns Remain Despite Amgen’s ‘Bare Commitment’ Not To Bundle Horizon Drugs

The commission seeks a preliminary injunction by 31 October to block the closing of the proposed Amgen-Horizon merger. Harvard Professor Aaron Kesselheim, FTC’s expert, says Amgen could circumvent a commitment not to bundle its and Horizon's products. The Pfizer-Seagen merger agreement also gets a second request for information.

FTC building
The FTC wants a preliminary injunction to block Amgen's acquisition of Horizon. • Source: Shutterstock

The US Federal Trade Commission doubled down on its efforts to halt the close of Amgen, Inc.’s proposed acquisition of Horizon Therapeutics plc until a final decision is made on its administrative complaint opposing the deal, asking a district court to issue a preliminary injunction by 31 October.

In a redacted 14 July memorandum supporting a preliminary injunction, the FTC and six states reiterated that post-merger, Amgen will be able to use rebates on its blockbuster drugs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By 

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

US FDA’s ‘Good Reputation’ For Science May Mean Loper Bright Not ‘Cataclysmic,’ Attorney Says

 

Bridget Dooling, a law school professor who reviewed draft regulations from the FDA and other agencies as an OMB attorney, said prior federal court decisions suggest judges typically defer to agency decisions based in science.

Europe’s UPC Issues Landmark Ruling On Second Medical Use Claims

 

The verdict by the Unified Patent Court in the dispute between Sanofi/Regeneron Pharmaceuticals and Amgen explains what companies should look out for when deciding whether infringement has taken place when it comes to second medical use patents.

Life After Loper: Vaping Case Shows US FDA Retains Considerable Deference

 
• By 

A US Supreme Court ruling in favor of the agency in an e-cigarette case has implications for drugs and other medical products as the justices decided not to disturb the FDA’s ‘change in position’ authority, while also creating a complex new landscape.

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By 

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By 

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.